



Press Release

**Genzyme India and Society for Indian Academy of Medical Genetics
join hands to train Indian doctors in clinical genetics**

***The MoU envisages a three-month joint fellowship program for Indian medical professionals
as well as educational and research support to SIAMG***

New Delhi, 7 April, 2013: To promote the science and practice of clinical genetics in India, Genzyme— one of the world’s foremost biotechnology companies and now a part of Sanofi worldwide – today announced a tie-up with the Society for Indian Academy of Medical Genetics (SIAMG) for a joint fellowship program for Indian medical professionals. This program of 3 months duration will be organized at the Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow and the first batch is set to begin from July this year.

The MOU was signed by **SIAMG President Dr Shubha R Phadke** and **Head of Genzyme for India & South Asia, Mr. Sandeep Sahney** at New Delhi. Under the terms of the agreement, Genzyme India will provide support to IAMG to help spread awareness about medical genetics in the country. The three-month fellowship program will be supported by Continuous Medical Education (CME) and medical workshops at the local as well as national level. IAMG, with the support of Genzyme, will also be bringing out a quarterly newsletter on genetics under the title of “Genetic Clinics.”

Commenting on the agreement, **Dr Shubha R Phadke** said- “We are very pleased to collaborate with Genzyme India to promote clinical genetics in the country. This partnership will have a significant impact on the newly-emerging field of genetic research and help strengthen India’s biotechnology capabilities to make a difference to the lives of the Indian people.”

On the same occasion, **Sandeep Sahney** highlighted this important agreement as one more example of demonstrating Genzyme’s commitment to India. In his words – “We are confident that these fellowships in clinical genetics will act as a catalyst for promoting academic excellence and applied research in this discipline in India as well as build clinical expertise.”



SIAMG President DrShubha R Phadke and Head of Genzyme for India & South Asia, Mr. Sandeep Sahney signed the MoU.

About SIAMG

<http://iamg.in/>

The Society for Indian Academy of Medical Genetics (IAMG) is a professional organization established by qualified medical geneticists from all over India. Its main objectives are to improve the quality and accessibility of clinical genetics services, promote education and research in medical genetics, and help integrate medical genetics research into patient care, thereby promoting the overall advancement of this medical discipline in India. The SIAMG serves as a forum of interaction for medical genetics centres across India to enable coordinated patient care, research and teaching in the field of medical genetics.

About Genzyme

www.genzyme.com

Genzyme, the pioneer in development and delivery of transformative therapies for over 30 years, was founded in 1981 in Boston, Massachusetts. Genzyme has evolved from a start-up with a handful of employees to becoming a big-league biotech company. In 2011, Genzyme was acquired by Sanofi, one of the world's largest pharmaceutical companies, and today benefits from its reach and resources as well as a shared commitment to improving the lives of patients.

Genzyme is the leader in developing and applying the most advanced technologies in life sciences, with many established products and services helping patients in nearly 100 countries around the world. Genzyme has long been known for its expertise in the class of rare genetic diseases known as Lysosomal Storage Disorders (LSDs). Though these remain the major focus area for Genzyme, the company has also

expanded – through in-house development and strategic acquisitions and partnerships – to other disease areas such as Thyroid Cancer and Multiple Sclerosis.

Genzyme's association with India goes back to 1999 when it began to support Indian patients suffering from rare genetic diseases called Lysosomal Storage Disorders (LSD). Since its formal inception in 2007, Genzyme has brought in its transformative therapies in India besides strengthening its efforts to support needy patients with its compassionate access program. Currently the prime focus for the Indian operations is on development of necessary benchstrength for proper awareness, diagnosis as well as treatment for patients suffering from rare genetic disorders.

###